Furthermore, either HDAC3 specific inhibitor RGFP966 or glutamine uptake inhibitor V9302 delayed the tumor growth, and the combination of RGFP966 and V9302 led the tumor partial or complete regression in vivo (Figure 7F–I). This evidence concerns the gene HDAC3 and neoplasm.